SEC Form 4 · accession 0001193125-26-365116
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amir Weiss
Officer — Chief Accounting Officer
Period of report
Aug 21, 2026
Accepted (ET)
Aug 25, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Aug 21, 2026 | S | 6,945 | $37.6133 | D | 13,071 | D | |
| Ordinary SharesF1 | Aug 21, 2026 | M | 2,500 | $19.61 | A | 15,571 | D | |
| Ordinary SharesF1 | Aug 21, 2026 | S | 2,500 | $37.6307 | D | 13,071 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3,F1 | $19.16 | Aug 21, 2026 | M | 2,500 | D | — | Mar 2, 2028 | Ordinary Shares | 2,500 | 7,502 | D |
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.61 to $31.62, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 having vested on March 2, 2022.